Protect Against Febrile Neutropenia: 1ml:3mg
Nombre del Producto: Pegylated Recombinant human factor estimulante de colonias de granulocitos de inyeccion
Package: 2ml Tube Vial, 1vial/Box, Medical bromide butyl rubber stopper、Neutral borosilicate glass vial
as manifested by febrile neutropenia, in Patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile Neutropenia.
Active Ingredient: Pegylated recombinant human granulocyte colony stimulating factor, excipients: Acetic acid- sodium acetate buffer, Sorbitol and Polysorbate 80.
Pegfilgratim is indicated to decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia.
Pegfilgratim should not be used for peripheral blood progenitor cell mobilization in patiens receiving hematopoietic stem cell transplantations.
Dosage and Administration
The recommended dosage of pegfilgratim is a single subcutaneous injection of 100μg/kg administered 48 hours after the administration of chemotherapy, once per chemotherapy cycle. The 100μg/kg fixed-dose formulation should not be used in infants, children, and smaller adolescents weighing less than 45 kg. Pegfilgratim should be visually inspected for discoloration and particulate matter before administration. Pegfilgratim should not be administered if discoloration or particulates are observed.
1. Use the pegfilgrastim 48 hours after chemotherapy regimens. Don’t use it during chemotherapy or prior to the chemotherapy.
2. During pegfilgrastim therapy, a complete blood count and platelet count should be obtained twice per week.
3. Pegfilgrastim should be given only under the guidance of doctors.
Mechanism of pegfilgrastim is granulocyte colony-stimulating factor combine with hematopoietic cell surface receptors to stimulate hyperplasia and prevent functional activation cell hyperplasia. Receptor binding mechanism and function of neutrophils showed: PEG-rhG-CSF and rhG-CSF has the same mechanism. Compared with rhG-CSF, PEG-rhG-CSF can reduce plasma clearance rate and extend half-life.
2-8℃; Avoid freezing; No shaking